Provectus Biopharmaceuticals Announces Investor Webinar for Fourth Quarter 2024 Conference Call
PROVECTUS BIOPHARMS (PVCT)
NASDAQ:AMEX Investor Relations:
provectusbio.com/financial-overview
Company Research
Source: GlobeNewswire
KNOXVILLE, Tenn., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) announced today that its Fourth Quarter 2024 Investor Update will be accessible by Zoom Webinar. The conference call will be held on Thursday, November 14, 2024 starting at 2 p.m. EST. The Fourth Quarter 2024 Investor Update webinar may be accessed by registering in advance here: https://us06web.zoom.us/webinar/register/WN_u628Om3GTyCrclcuZckXNg?_ga=2.250060678.1412167732.1728519054-492896892.1650903731#/registration. About Provectus Provectus Biopharmaceuticals is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases that are based on a class of bioactive synthetic small molecules called halogenated xanthenes. The Company’s lead molecule is named Rose Bengal Sodium. Provectus’s small molecule drug platform includes: Clinical development programs in oncology, dermatology, and ophthalmology,In vivo proof-of
Show less
Read more
Impact Snapshot
Event Time:
PVCT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PVCT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PVCT alerts
High impacting PROVECTUS BIOPHARMS news events
Weekly update
A roundup of the hottest topics
PVCT
News
- Provectus Biopharmaceuticals Launches VisiRose, Provectus's Founded Entity for Pharmaceutical-grade Rose Bengal Sodium-based Treatments in Ophthalmology [Yahoo! Finance]Yahoo! Finance
- Provectus Biopharmaceuticals Launches VisiRose, Provectus’s Founded Entity for Pharmaceutical-grade Rose Bengal Sodium-based Treatments in OphthalmologyGlobeNewswire
- VisiRose Introduces Revolutionary Therapy for Severe Eye Infections [Yahoo! Finance]Yahoo! Finance
- VisiRose Introduces Revolutionary Therapy for Severe Eye InfectionsAccesswire
- Provectus Biopharmaceuticals Announces Fourth Quarter 2024 Conference CallGlobeNewswire
PVCT
Sec Filings
- 12/11/24 - Form 8-K
- 12/6/24 - Form SC
- 12/5/24 - Form 8-K
- PVCT's page on the SEC website